

Effect Of SglT2 Inhibitors On Hypertension, In Diabetic And Non-Diabetic Patients

Shalabh Jauhari¹, Shatakshi Rai², Reenoo Jauhari*

¹Associate Professor, Department of Microbiology, Government Doon Medical College, Dehradun, Dehradun. drsjauhari09@gmail.com,

² Student, School of Pharmaceutical Sciences, Department of Pharmacy Practice, SGRRU, Patel Nagar, Dehradun. raishatakshi7@gmail.com,

*Associate Professor, School of Pharmacy, Graphic Era Hill University, Clement town, Dehradun. reenoojauhari1309@gmail.com,

*Corresponding author.

DOI: 10.47750/pnr.2023.14.S03.07

Abstract

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The classical classification of diabetes as proposed by the American Diabetes Association (ADA) in 1997 as type 1, type 2, other types, and gestational diabetes mellitus (GDM) is still the most accepted classification and adopted by ADA. Type 1 Diabetes Mellitus is a result of impaired insulin secretion, Type 2 Generally, a Negative feedback mechanism is there that controls homeostasis of our body, but there is no negative feedback mechanism for the reabsorption of glucose from the proximal renal tubule. Sodium–glucose cotransporter-2 (SGLT2) inhibitors are the drugs that control the reabsorption of glucose from the proximal renal tubule. It has become clear that SGLT2 inhibitors not only improve the blood glucose level, but also show cardiovascular and renal protective effects irrespective of the reduction of blood glucose in patients with type 2 diabetes mellitus (T2DM). There is an activation of sympathetic nervous system which causes the development of hypertension in type 2 diabetes mellitus (T2DM) patients. In this review we will discuss about various cardiovascular protection done by SGLT2 Inhibitors in both diabetic and non-diabetic patients.

Keywords: Type 2 Diabetes Mellitus (T2DM), Sodium- Glucose cotransporter-2 (SGLT2) inhibitors, Hypertension, Cardiovascular.

Introduction

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The classical classification of diabetes as proposed by the American Diabetes Association (ADA) in 1997 as type 1, type 2, other types, and gestational diabetes mellitus (GDM) is still the most accepted classification and adopted by ADA [1]. Type 1 Diabetes Mellitus is due to impaired insulin secretion, Type 2 Generally, a Negative feedback mechanism is there that controls homeostasis of our body, but there is no negative feedback mechanism for the reabsorption of glucose from the proximal renal tubule. Sodium–glucose cotransporter-2 (SGLT2) inhibitors are the drugs that control the reabsorption of glucose from the proximal renal tubule. It has become clear that SGLT2 inhibitors not only improve the blood glucose level, but also show cardiovascular and renal protective effects irrespective of the reduction of blood glucose in patients with type 2 diabetes mellitus (T2DM). There is an activation of sympathetic nervous system which causes the development of hypertension in type 2 diabetes mellitus (T2DM) patients. Diabetes Mellitus is via peripheral actions of insulin and Gestational Diabetes is a form of T2DM but occurs in pregnant women [2].

Hypertension (HTN) is present in more than 50% of patients with diabetes mellitus (DM) and contributes significantly to both micro and macrovascular disease in diabetes. DM and HTN share several pathophysiologic mechanisms including: inappropriate activation of the renin angiotensin aldosterone system (RAAS), oxidative stress secondary to excessive production of reactive oxygen species (ROS), inflammation, impaired insulin mediated vasodilatation, increased sympathetic nervous system (SNS) activation, dysfunctional innate and adaptive immune responses and abnormal renal handling of sodium [3-6].

Pharmacokinetics and Pharmacodynamics of SGLT2 Inhibitors

SGLT2 Inhibitors are independent of pancreatic endocrine secretion and can be used in monotherapies or can be co-administered with clinically prescribed antidiabetic agents. [7-9] The pharmacokinetic of SGLT2 Inhibitors are:

- Bioavailability of the drugs varies from 60% to 80%.
- Therapeutic dose may range from 100-300mg (Canagliflozin), 5-10mg (Dapagliflozin), 10-25MG (Empagliflozin) and 25-50mg (Ipragliflozin).
- Drug is eliminated via urine and feces in an inactive metabolite form.
- The drugs are metabolized via Glucuronidation reaction.
- Plasma protein binding is 90%-99%.

The SGLT2 are responsible for the reabsorption of 90% glomerular glucose and its inhibitors can only suppress up to 30-50% of total. As the drugs are actively eliminated/ reabsorbed from the same site, thus reducing the blocked transporters along the proximal tubule [10].

SGLT2 Inhibitor and Hypertensive effect

There is not a single mechanism that can explain the favorable effects of SGLT2 Inhibitors on cardiovascular outcomes. There is an indirect improvement of cardiac functions by the inhibition of SGLT2 which occurs via natriuresis followed by reduction of volume overload. Several different theories have been proposed to explain the profound salutary effects of SGLT2 inhibitor on cardiovascular outcomes. It is suggested that inhibition of SGLT2 decreases ventricular overload through its diuretic effects thereby reducing blood pressure [11].

Recently in EMPA-REG OUTCOME trial, it was reported that the SGLT2 inhibitor empagliflozin significantly reduce the rate of primary composite cardiovascular outcome and also prevent death from any cause in patients with T2DM which are at risk of developing a cardiovascular disease. This was the first study which reported that an antidiabetic agent reduce mortality in patients with T2DM. The additional use of SGLT2 inhibitors significantly reduced the onset and worsening of nephropathy in the subgroup analysis of the EMPA-REG OUTCOME trial [12-13].

Zhao Li conducted a retrospective observational study both in vivo and ex vivo in diabetic and non-diabetic groups with SGLT2 Inhibitors (Canagliflozin, Dapagliflozin and Empagliflozin) and the results suggested that the drugs are cardioprotective irrespective of the diabetic status. Inhibition of SGLT2 protects the heart through natriuresis, metabolic shift, improved Ca²⁺ handling, hypertension and reduction of cardiac fibrosis. So, the study suggested that SGLT2 Inhibitors can also be given to non-diabetic patients as it had beneficial effects in them [14].

Kazuomi Kario et al. conducted a randomized, placebo-controlled SACRA Study (SGLT2 inhibitor and Angiotensin Receptor Blocker [ARB] Combination Therapy in Patients with Diabetes and Uncontrolled Nocturnal Hypertension) which investigated changes in blood pressure (BP) with empagliflozin plus existing antihypertensive therapy in 2018. There was a 12week study conducted in which one group was given a placebo drug and another group was given empagliflozin 10mg. It was observed that there was a reduction in the night time BP. The numeric difference observed in placebo was (-4.3 mm Hg) and the reduction from baseline with empagliflozin was (-6.3 mm Hg). So, the study concluded that the use of SGLT2 Inhibitors has a beneficial effect in lowering blood pressure in T2DM patients with hypertension [15].

SGLT2 inhibitors reduce central sympathetic overactivity, probably by suppressing renal afferent signaling to the brain. They decrease sympathetic outflow from the brain to the kidney and alters the pressure–natriuresis relationship so that the kidneys excrete more sodium and water at a given pressure, thereby improving fluid retention. It may also suppress the rennin Angiotensin system (RAS) thereby helping in lowering the blood pressure and providing cardiovascular protective effect [16]. A study of SGLT2 Inhibitors (dapagliflozin) was conducted the results were analyzed in a trial known as DECLARE-TIMI 58, in which the T2DM patients were given dapagliflozin and their effect on cardiovascular outcome was studied. It is a known fact that dapagliflozin causes blood pressure reduction. A phase III study was conducted and the effect of dapagliflozin on blood pressure was studied on the T2DM patients with hypertension. The results of the study were that there was a difference of -4.28mmHg between the group on dapagliflozin and a renin-angiotensin-aldosterone system blocker and the group on an antihypertensive alone. It is also suggested that the use of dapagliflozin reduces diabetic nephropathy [17-18].

As we already know that SGLT2 inhibitors works by reducing blood pressure and restores tubuloglomerular feedback. Sua Kim et al. conducted research in 2019 in which he studied the effect of empagliflozin in which he demonstrated that the use of SGLT2 Inhibitors was effective at controlling salt-sensitive hypertension, which was induced by renal mass reduction in nondiabetics. The study concluded that there is upregulation of HIF-1 α (Hypoxia inducible factor, a complex protein which helps in body's response to low oxygen concentration) which contributes to the protective effects of SGLT2 inhibitors on blood pressure, and empagliflozin exerts anti-inflammatory action in non-diabetic kidney disease as well [19].

Even though SGLT2 inhibitors are not approved as antihypertensive agents, there are various trials which reported SGLT2 inhibitors reduces systolic and diastolic blood pressure by 3–7 and 2 mmHg, respectively [20-21]. Blood pressures reduction is independent of the diseased status, so, it is interesting to note that blood pressure reduction with SGLT2 Inhibitors may occur by inhibiting SGLT2 receptors which prevent reabsorption of filtered glucose at the proximal convoluted tubule and leads to insulin-independent glycosuria which results in weight reduction, diuretic effect and reduction of various sympathetic activity. The drug also reduces the arterial stiffness, thus also suggesting to vascular effects [22-23]. The effects on blood pressure are not restricted to daytime, as nocturnal blood pressure is also decreased, which is a predictor for cardiovascular and renal disease progression [24-25]. SGLT2 Inhibitors might also improve cardiac preload by lowering plasma volume and causing osmosis and natriuretic diuresis, secondary to urinary sodium and glucose excretion. These processes can beneficially influence kidneys and heart thereby helping in blood pressure reduction. Therefore, the use of SGLT2 Inhibitors in non-diabetic kidney disease patients is also beneficial [26-27].

Recently a DAPA-HF trial was published in which the effect of SGLT2 Inhibitor (dapagliflozin) was studied in both diabetic and non-diabetic groups. It was found that there was beneficial effect on cardiovascular outcomes, decreased heart rate and there was some decline in glomerular filtration rate in patients which were diabetic and non-diabetic [28]. Tikkanen et al. also investigated the effectiveness of the empagliflozin on blood pressure using 24hour ambulatory blood pressure monitoring. It was a randomized study on 800 type 2 diabetic patients over 60 years of age. The subjects taken were either normotensive (<140/90 mmHg) or had stage 1 hypertension (\geq 140/90 or <160/99 mmHg). The dose given was either 10mg daily, 25mg daily or placebo and at the same the HbA1c levels were also analyzed over 12 weeks study. The end point of the study was the change in the mean systolic blood pressure as there was a differenced of 4mmHg from the placebo. There was a significant reduction of both systolic and diastolic blood pressure, 4/2mmHg at 25mg empagliflozin as compared to the placebo. As the drugs have salutary effects (i.e., blood pressure– lowering and weight-reducing effects) and are safe as they are not associated with hypoglycemia except when given in combination with insulin or sulfonylurea so furthers studies should be done to check the beneficial effect of these class of drugs [29].

Lakshini Y. Heart et al. conducted a study on neurogenic hypertensive mouse model, known as the Schlager (BPH/2J) interaction between sympathetic hyperactivity and SGLT2 regulation was analyzed. The study was carried out for 18-

20 weeks on non-diabetic mouse and the results were then analyzed. the results of the study concluded that there was reduction in blood pressure as well as glucose homeostasis was also maintained by the use of SGLT2 Inhibitor dapagliflozin. Further the study also demonstrated that dapagliflozin also controls the elevation of both systolic and diastolic blood pressure in mouse. It is essential that future studies aim to assess whether SGLT2 inhibition will also result in sympatho-inhibition in human hypertensive subjects [30]

Recently there are various studies which are going on to check the benefits of SGLT2 Inhibitors on cardiovascular outcomes independent of the patients having diabetes.

Conclusion

SGLT2 Inhibitors significantly reduce HbA1c levels but also helps in reducing systolic blood pressure in patients with T2DM. Generally, canagliflozin, dapagliflozin and empagliflozin are the drugs which are used in the studies to determine the beneficial effect of SGLT2 Inhibitors in both T2DM and non-diabetic patients. There is some amount of clinical data available which provides information regarding the use of SGLT2 Inhibitors in T2DM patients with hypertension as the drug also act as the cardioprotective agent, increases diuresis, maintain glucose homeostasis by inhibiting its reabsorption from the proximal tubule thereby reducing blood pressure. There are still various clinical trials on run to provide the beneficial effect of SGLT2 Inhibitors in non-diabetic patients, though various pre-clinical studies on animals have been don which reported the beneficial effect of SGLT2 Inhibitors in non-diabetic groups. Its beneficial effects in humans are yet to be done in clinical trials. But there are various studies which demonstrated that the SGLT2 Inhibitors also have a significant cardioprotective property and nephroprotective property irrespective of its antidiabetic action.

References

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2014; 37 Suppl 1: S81-S90 [PMID: 24357215 DOI: 10.2337/dc14-S081].
2. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nat Rev Endocrinol.* 2018 Feb;14(2):88-98. [PubMed: 29219149].
3. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. *Hypertension.* 2001; 37:1053–1059. [PubMed: 11304502].
4. Sowers JR, Whaley-Connell A, Hayden M. The role of overweight and obesity in the cardiorenal syndrome. *Cardiorenal Med.* 2011; 1:5–12. [PubMed: 22258461].
5. Sowers JR. Diabetes mellitus and vascular disease. *Hypertension.* 2013; 61(5):943–7. [PubMed:23595139].
6. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care.* 1993; 16:434–444. [PubMed: 8432214].
7. Matthaehi S, Bowering K, Rohwedder K, Grohl A, Parikh S., Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. *Diabetes Care* 2015; 38: 365-372.
8. Wilding Jp, Woo V, Soler Ng, Pahor A, Sugg J, Rohwedder K, Parikh S, Studiengruppe Dapagliflozin. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin. *Ann Intern Med* 2012; 156: 405- 415.
9. Neal B, Perkovic V, De Zeeuw D, De Zeeuw D, Mahaffey Kw, Fulcher G, Ways K, Desai M, Shaw W, Capuano G, Alba M, Jiang J, Vercruyse F, Meininger G, Matthews D; Canvas Trial Collaborative Group. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. *Diabetes Care* 2015; 38: 403-411.
10. F.A. Ribola, F.B. Cançado, J.H.M. Schoueri, V.F. De Toni, V.H.R. Medeiros, D. Feder, Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus, Department of Pharmacology of ABC Medical School, São Paulo, Brazil. *European Review for Medical and Pharmacological Sciences* 2017; 21: 199-211.
11. Verma S, McMurray JJV, Cherney DZI. The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. *JAMA Cardiol* 2017; 2:939–940.
12. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med.* 2015;373:2117–28.
13. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. *N Engl J Med.* 2016;375:323–34.
14. Zhao Li. Further insights into cardiovascular outcomes in diabetic and non-diabetic states: inhibition of sodium-glucose co-transporters. Department of Pharmaceutical Sciences, School of Pharmacy and Physician Assistant Studies, University of Saint Joseph, 229 Trumbull ST, Hartford, 06103, Connecticut, USA. e-mail: zhaoli@usj.edu DOI: 10.1097/XCE.0000000000000178.
15. Kazuomi Kario, MD, PhD, Kenta Okada, MD, PhD Mitsutoshi Kato, MD, PhD Masafumi Nishizawa, MD Tetsuro Yoshida, MD, PhD Tsuguyoshi Asano, MD Kazuaki Uchiyama, MD Yawara Nijijima, MD Tomohiro Katsuya, MD, PhD Hidenori Urata, MD, PhD Jun-ichi Osuga, MD, PhD Takeshi Fujiwara, MD, PhD Shoji Yamazaki, PhD Naoko Tomitani, BSc Hiroshi Kanegae, BSc. Twenty-Four-Hour Blood

- Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension Results From the Randomized, Placebo-Controlled SACRA Study. *Circulation*. 2019;139:2089–2097. DOI: 10.1161/CIRCULATIONAHA.118.037076.
16. Polhemus DJ, Trivedi RK, Gao J, Li Z, Scarborough AL, Goodchild TT, et al. Renal sympathetic denervation protects the failing heart via inhibition of neprilysin activity in the kidney. *J Am Coll Cardiol* 2017;70:2139–53.
 17. GHOSH RK, BANDYOPADHYAY D, HAJRA A, BISWAS M, GUPTA A. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: a comprehensive review of clinical and preclinical studies. *Int J Cardiol* 2016; 212: 29-36.
 18. WEBER MA, MANSFIELD TA, CAIN VA, IQBAL N, PARIKH S, PTASZYNSKA A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Diabetes Endocrinol* 2016; 4: 211-220.
 19. Sua Kim Chor Ho Jo1 Gheun-Ho Kim1,2 Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats. *Hypertension Research* (2019) 42:1905–1915. <https://doi.org/10.1038/s41440-019-0326-3>.
 20. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. *J Am Soc Hypertens*. 2014;8(5):330–9.
 21. Busch RS, Kane MP. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes. *Postgrad Med*. 2017;129(7):686–97.
 22. Sano M. A new class of drugs for heart failure: sGLT2 inhibitors reduce sympathetic overactivity. *J Cardiol*. 2018;71(5):471–6.
 23. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity induced hypertension: interaction of neurohumoral and renal mechanisms. *Circ Res*. 2015;116(6):991-1006.
 24. Kario K, Okada K, Kato M et al. 24-Hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study. *Circulation* 2018; 139: 2089–2097.
 25. Mehta R, Drawz PE. Is nocturnal blood pressure reduction the secret to reducing the rate of progression of hypertensive chronic kidney disease? *Curr Hypertens Rep* 2011; 13: 378–385.
 26. Eickhoff MK, Dekkers CCJ, Kramers BJ et al. Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors. *J Clin Med* 2019; 8: E779.
 27. Lambers Heerspink HJ, de Zeeuw D, Wie L et al. Dapagliflozin a glucoseregulating drug with diuretic properties in subjects with type 2 diabetes. *Diabetes ObesMetab* 2013; 15: 853–862.
 28. McMurray JJV, Solomon SD, Inzucchi SE et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med* 2019; 381:1995–2008.
 29. Tikkanen I, Narko K, Zeller C, et al.; EMPAREG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. *Diabetes Care* 2015;38: 420–428.
 30. Lakshini Y, Herat, Aaron L, Magno, Caroline Rudnicka, Jana Hricova, Revathy Carnagarin, Natalie C. Ward, Angelique Arcambal, Marcio G. Kiuchi., Geoff A. Head, Markus P. Schlaich, Vance B. Matthews, SGLT2 Inhibitor-Induced Sympathoinhibition A Novel Mechanism for Cardiorenal Protection College Of Cardiol Ogy Foundat Ion. Herat et al. *JACC: BASIC TO TRANSLATION A LSCIENCE VOL.5,NO.2,2020 Sympathoinhibition Induces Cardiorenal Protection FEBRUARY 2020:169–179.*